Ketamine impact on intraocular pressure of children: a systematic review and qualitative synthesis of evidence

Impacto de la ketamina sobre la presión intraocular en niños: revisión sistemática y síntesis cualitativa de la literatura

Joaquín O. Ruiz-Villa, Daniela A. Jaramillo-Rivera, Lina M. Pineda-Gutierrez

a Universidad Nacional de Colombia, Bogotá, Colombia
b Universidad Nacional Autónoma de México, Mexico City, Mexico.

Abstract

Introduction: Intraocular pressure (IOP) measuring in children is a defiant challenge for ophthalmologists due to the unwillingness to collaborate of patient; therefore, it is necessary to perform these examinations under anesthesia (EUA) in order to facilitate the measuring. Among the anesthetic drugs, ketamine is safe in both children and adults and different studies have stated that it might have lower impact on IOP than other anesthetic drugs.

Objective: To determine whether ketamine has any impact on IOP in pediatric patients. Also, defining if this drug can be recommended to perform EUA in children with glaucoma.

Methods: Systematic review of literature was conducted including articles published in Ovid, PubMed, ScienceDirect, Cochrane, and LILACS from January 1970 to February 2019. The studies included were those with patients aged under 18 years to whom ocular tonometry had been performed. Intervention consisted on administering ketamine and the primary outcome to be assessed was changes in IOP after ketamine administration. Intra operative and postoperative complications were also assessed as secondary outcomes. Report is made according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines.

Results: Nine studies were selected for the systematic review. The administration of ketamine and its effects on intraocular pressure values were described in 293 children. Three studies found rising of intraocular pressure and 6 little or clinically not significant changes.

Conclusion: In children, there is low-quality evidence that suggests a minimal impact of ketamine on IOP modification. Better quality studies (controlled clinical trials) are required to clearly recommend the use of ketamine to perform EUA in children with glaucoma.

Resumen

Introducción: La medición de la presión intraocular (PIO) en niños es desafiante para el oftalmólogo debido a la falta de colaboración por parte del paciente; esto hace necesario llevar a cabo estos exámenes bajo anestesia (EBA) para facilitar la medición. Entre los...
medicamentos anestésicos generales, la ketamina es segura tanto en adultos como en niños, y se ha planteadado en varios estudios que puede tener menor efecto sobre la PIO que otros fármacos anestésicos.

**Objetivo:** Determinar si la ketamina tiene un efecto sobre la presión intraocular en población pediátrica. De esta manera, definir si es recomendable utilizar este medicamento para realizar los exámenes bajo anestesia general en niños con diagnóstico de glaucoma.

**Métodos:** Se realizó una revisión sistemática de la literatura de los artículos publicados en Ovid, PubMed, ScienceDirect, Cochrane y LILACS desde enero de 1970 hasta febrero de 2019. Se incluyeron aquellos estudios con pacientes menores de 18 años en quienes se realizó tonometría ocular. La intervención fue la administración de ketamina y se evaluó como desenlace primario los cambios en la PIO después de su administración. También se evaluaron las complicaciones intra y posoperatorias como desenlaces secundarios. Se reporta de acuerdo con los lineamientos PRISMA.

**Resultados:** Un total de nueve artículos se incluyeron para la revisión sistemática; en 293 niños se describió la administración de ketamina y medición de presión intraocular. Se requieren estudios comparativos para establecer cambios mínimos o sin significación clínica.

**Conclusiones:** En niños existe evidencia de baja calidad que sugiere un impacto mínimo de la ketamina sobre la modificación en la PIO. Se requieren estudios de mejor calidad (ensayos clínicos controlados) que permitan crear una recomendación clara sobre el uso de este medicamento para realizar EBA en niños con glaucoma.

**Introduction**

High intraocular pressure (IOP) is the main risk factor for glaucoma and the only modifiable condition of this pathology; therefore, measuring IOP is essential to diagnose, follow-up and treat this illness. In pediatrics, this measuring is especially complex, as stillness and collaboration are required from patients during tonometry, conditions difficult to meet when it comes to children. In adults, the IOP values range from 9 to 21 mm Hg, but, in children, normal values are not that clear. Several authors have measured and established IOP values in healthy children, normal values are not that clear. Several authors have measured and established IOP values in healthy children and results range from 13.3 ± 3.4 to 17.7 ± 2.7 mm Hg. Glaucoma is a broad and varied pathology; it causes blindness at long-term and, in children, it characterizes by having a rapid progression, severe clinical condition and difficult management. Incidence of pediatric glaucoma is 1/10,000 in newborn alive children. According to the World Health Organization, it is part of the first 5 causes of blindness at world level in the general population and the fourth in Colombia in pediatric population.

Blindness in children ranges from 0.3 to 1.5 per 1000, according to the social and economic conditions of the population. Early diagnosis and appropriate control of the IOP are the treatment cornerstone, in order to prevent severe ocular morbidity. New non-contact tonometry technologies seem the ideal for pediatric patients, with acceptable accuracy and concordance in comparison with the gold standard of Goldmann’s applanation tonometry, however, access to these technologies is yet limited in many scenarios.

Due to their inability to cooperate, newborn, nursing babies, and children cannot tolerate the ophthalmoscopic examination and IOP measuring; therefore, general anesthesia guarantees an accurate evaluation of the eye. Anesthetic intervention may alter the accuracy of the IOP measurement; hypertension, increase in the central venous pressure, hypoxia, and hypoventilation increase IOP, while most anesthetics (inhaled, inducers, benzodiazepines, and opioids) reduce it. Some authors agree that ketamine may increase IOP or produce a negligible effect in it. Providing a balanced sedation, analgesia, low respiratory, and cardiovascular depression, ketamine is an interesting alternative to provide anesthesia to pediatric patients requiring an examination.

Several authors support the hypothesis that the IOP after ketamine administration is the most accurate representation of IOP in awake calmed patients. The purpose of this study is describing changes in intraocular pressure values in pediatric patients after administering ketamine as general anesthetic.

**Methods**

A systematic review of literature was conducted by consulting the PubMed, LILACS, Ovid, Cochrane, and ScienceDirect databases, through search strategies that may be consulted in Annex 1. The research protocol was not recorded in databases (Prospective Register of Systematic Reviews); nonetheless, this was not subject to modifications during the execution of the project.

The inclusion criteria comprised articles published from 1970 to February 2019, observational descriptive studies, cases and controls, randomized controlled cohorts and clinical trials in English, Spanish, French, and Portuguese languages. Studies non-complying with these characteristics were excluded. The PICO structure of studies should comprise patients aged under 18 years who had been performed an ocular tonometry, intervention was the administration of ketamine intravenously (IV), intramuscularly (IM), orally (O), or intrarectally for sedation or anesthesia during the examination, placebo or the administration of another anesthetic (sevofoflurane, halothane, propofol, etomidate, thiopental) (C), Intraocular pressure measured (O). This was compared with placebo or the administration of another anesthetic (sevofoflurane, halothane, propofol, etomidate, thiopental), and intraocular pressure measured after the administration of medicine was established as outcome. Figure 1 shows...
the inclusion and exclusion of articles with their respective causes.

Results from search in each database were compiled in a form previously created in Excel by the authors; such form contains authors, title, publication date, and abstract of each article. Independently, each author identified articles subject to evaluation according to their title and abstract. Disagreements were solved by consensus. Articles included are qualitatively summarized in Table 1. The absolute variation value of IOP after administering ketamine as described above was compiled as primary outcome; in case of absence of absolute values, the variation percentage of IOP would be used as alternative. In studies reporting safety data, safety variables on respiratory complications, psychomotor agitation, and sedation were used as secondary outcomes.

Observational studies were evaluated through the quality assessment tool from the National Institute of Health (QAT-NIH) for observational studies. In the case of randomized clinical trials, the QAT-NIH for randomized controlled studies was used. In addition, the Cochrane risk-of-bias tool was used (Fig. 2a and 2b). An additional search was made on the preliminary results of research and in-progress researches without final results, finding no further information for the systematic review. No study was subject to be included in a meta-analysis; therefore, a qualitative synthesis of literature was performed.

Results

A total of 4519 studies were found, of which 4487 did not correspond to planned characteristics for the systematic review as these were articles on trials conducted in adults, most of them did not include the administration of ketamine in their methodology, did not include measuring of intraocular pressure or were not presented in the languages described in the inclusion criteria (Fig. 1).
| Reference                  | Study design                  | Population                      | Age range (average) | Intervention                        | Result                                                                 | QAT-NIH quality |
|----------------------------|-------------------------------|---------------------------------|---------------------|-------------------------------------|------------------------------------------------------------------------|-----------------
| Yoshikawa and Murai24      | Prospective Observational     | 15 Patients                     | 4-7 Years           | Ketamine 5 mg/kg IM                 | Increase in IOP between 18% and 37%                                    | Poor            |
| Ausinsch et al25           | Prospective Observational     | 10 Healthy children aged between 2 and 10 years | 2-10 Years (5.7) | Ketamine 8 mg/kg IM in both groups, second dose of 1mg/kg in group 2 | Slight, not significant decrease in IOP                                | Poor            |
| Nagdeva et al26            | Randomized Double-Blind Trial | 40 Children: 6 females and 34 males | 1-6 Years (3.8)    | Ketamine 3 or 6 mg/kg IM            | Increase in IOP with doses of 6 mg/kg, without changes in IOP with doses of 3mg/kg | Acceptable      |
| Blumberg et al27           | Randomized Non-Blind Trial    | 30 Children: 15 females and 15 males | 1-216 Months (62)   | Ketamine 5-7 mg/kg IM               | No significant changes in IOP reported; with 7% lower ketamine compared with the baseline value | Acceptable      |
| Jones et al28              | Retrospective Case Series     | 8 Children aged between 26 and 89 months | 26-89 Months (55.4) | Ketamine 5 mg/kg IM or 2mg/kg IV    | No significant changes in IOP                                         | Poor            |
| Halstead et al30           | Non-Inferiority Clinical Trial| 80 Children: 49 males and 31 females | 1-15 years          | Ketamine 1.6mg/kg IV                | No significant increase in IOP                                        | Acceptable      |
| Drayna et al29             | Prospective Observational     | 25 Patients: 18 males and 7 females | 7-17 years (11)    | Ketamine 0.96–4 mg/kg IV            | No significant changes in IOP                                         | Acceptable      |
| Wadia et al31              | Prospective Observational     | 60 Healthy children: 49 males and 11 females | 8-18 years (11)   | Ketamine 0.5mg/kg/min IV            | Slight increase in IOP without clinical relevance                     | Acceptable      |
| Van der Walt et al32       | Prospective Observational     | 25 Children: 14 males and 11 females | 2 and 88 months (29) | Ketamine 2 mg/kg IV in bolus and then 4 mg/kg/h IV | Increase in IOP after infusion                                       | Good            |

IM = intramuscular, IOP = intraocular pressure, IV = intravenous, QAT-NIH = Quality Assessment Tool from the National Institute of Health.

Source: Authors.
Nine studies were included, of which 3 were clinical trials, 2 of them conducted in patients without glaucoma diagnosis and 1 in patients with glaucoma or suspected glaucoma. General results and a summary on the studies are shown in Table 1.

The Yoshikawa and Murai study intended to assess the impact of ketamine on intraocular pressure in healthy children; patients aged 4 to 7 years were included and the intervention conducted consisted on administering ketamine doses at 5mg/kg IM, without premedication. Authors explained to have taken a basal IOP before the injection, followed by measurements every 5 minutes up to 30 minutes after injection. Authors do not describe in their methodology the tests run to assess the statistical significance of results; nevertheless, they reported a statistically significant increase in IOP from minute 5 (18% increase in measurements, $P < 0.001$) up to minute 15 (37% increase in measurements, $P < 0.005$), and return to basal values in minute 30 with $P < 0.4$. This change was accompanied by increase in blood pressure and heart rate in the first 5 minutes after injection. A patient with strabismus was reported with an early drop in IOP after the administration of the drug. Authors did not describe respiratory, cardiovascular or behavioral complications during the study.

Ausinsch et al study sought to assess the impact of ketamine on IOP in children with healthy eyes; therefore, 10 children without ocular pathology evidence were recruited. All children were premedicated with atropine 0.02mg/kg IM, and 5 of them received 1.1mg/kg IM of meperidine and 4.4mg/kg IM of pentobarbital. Basal values were taken with ocular instillation of proparacaine hydrochloride ophthalmic solution in both eyes. The study was divided in 2 stages. Initially, all patients received 8mg/kg of ketamine IM and measurements were taken at 5, 10, 15, and 20 minutes. Then, a second dose of 1 mg/kg of ketamine was administered to all patients and 5 of them additionally received 0.8mg/kg of d-tubocurarine IV, these were intubated 5 minutes later and received anesthetic treatment with nitrous oxide. IOP was measured at 5, 10, and 15 minutes after the first dose. Authors found decrease between the average basal IOP and after induction with ketamine (22.2 ± 4.8 vs.
with halothane up to 4%. Following the Güedel (100mg/kg). Anesthetic induction was through inhalation 60 to 90 minutes before surgery with oral triclofos vascular aneurisms, psychiatric disorders, and seizure general anesthesia, were included. Patients with previously Society of Anesthesiologists (ASA) I, weighting more than 25 kg and with 30 to 90-minute scheduled surgeries under general anesthesia, were included. Patients with previously high IOP, endocranial hypertension, open ocular trauma, vascular aneurisms, psychiatric disorders, and seizure syndromes were dismissed. All patients received premedication 60 to 90 minutes before surgery with oral triclofos (100mg/kg). Anesthetic induction was through inhalation with halothane up to 4%. Following the Güedel’s planes, once patients reached surgical anesthesia, they continued administering halothane at 1%. 10 minutes after induction, patients were randomized to groups of low doses (3mg/kg) or high doses (6mg/kg) of ketamine. The drug was administered IM in the deltoid muscle and measuring of IOP was taken every 5 minutes. During 20 minutes no surgical stimulation was allowed in the patient. There was blinding of the observer taking measurements on the administered dose, who measured IOP in both eyes unless 1 of them were intended for surgery, in which case the eye to be operated was excluded.

Both groups were comparable in terms of demographic distribution (gender, weight, age). In each group, data were subject to repeated measures analysis of variance and compared with measurements defined as basal using the Student t test. The induction dose group reported increase in IOP 5 and 10-minute measurements (basal 10.8±2.2 mm Hg, 5 minutes 12.6±2.8 mm Hg and 10 minutes 11.9±2.5 mm Hg, P<0.001). The low-dose group reported no change in IOP. However, when comparing the values of IOP at minute 10 and 15 of both groups, no statistically significant difference was reported; results were as follows: basal 11.4±2.0, 11.1±2.2 mm Hg at 5 minutes, and 11.1±2.2 mm Hg at 10 minutes. With respect to complications, the high-dose group reported a more frequent airway obstruction, with 18 patients, in comparison with 4 from the low-dose group (P<0.001). Likewise, the postoperative sedation was higher in the higher dose group (P<0.001). Two dissociative reactions at the moment of waking up were reported, both in the high-dose group.

Nagdev et al26 sought to answer the same question through a randomized double-blind clinical trial; therefore, 40 pediatric patients classified as category I by the American Society of Anesthesiologists (ASA) I, weighing more than 25 kg and with 30 to 90-minute scheduled surgeries under general anesthesia, were included. Patients with previously high IOP, endocranial hypertension, open ocular trauma, vascular aneurisms, psychiatric disorders, and seizure syndromes were dismissed. All patients received premedication 60 to 90 minutes before surgery with oral triclofos (100mg/kg). Anesthetic induction was through inhalation with halothane up to 4%. Following the Güedel’s planes, once patients reached surgical anesthesia, they continued administering halothane at 1%. 10 minutes after induction, patients were randomized to groups of low doses (3mg/kg) or high doses (6mg/kg) of ketamine. The drug was administered IM in the deltoid muscle and measuring of IOP was taken every 5 minutes. During 20 minutes no surgical stimulation was allowed in the patient. There was blinding of the observer taking measurements on the administered dose, who measured IOP in both eyes unless 1 of them were intended for surgery, in which case the eye to be operated was excluded.

Both groups were comparable in terms of demographic distribution (gender, weight, age). In each group, data were subject to repeated measures analysis of variance and compared with measurements defined as basal using the Student t test. The induction dose group reported increase in IOP 5 and 10-minute measurements (basal 10.8±2.2 mm Hg, 5 minutes 12.6±2.8 mm Hg and 10 minutes 11.9±2.5 mm Hg, P<0.001). The low-dose group reported no change in IOP. However, when comparing the values of IOP at minute 10 and 15 of both groups, no statistically significant difference was reported; results were as follows: basal 11.4±2.0, 11.1±2.2 mm Hg at 5 minutes, and 11.1±2.2 mm Hg at 10 minutes. With respect to complications, the high-dose group reported a more frequent airway obstruction, with 18 patients, in comparison with 4 from the low-dose group (P<0.001). Likewise, the postoperative sedation was higher in the higher dose group (P<0.001). Two dissociative reactions at the moment of waking up were reported, both in the high-dose group.

Blumberg et al27 reported results from a randomized clinical trial published in 2007. This study included patients of any age with glaucoma or suspected glaucoma scheduled for tonometry with anesthesia due to low collaboration. Contingency tables were used to compare characteristics of children in the 2 arms of the study and changes were valued in several monitoring periods (2, 4, 6, and 8 minutes).

No standardization was conducted in the administration or not of premedication; some patients received midazolam O (0.5–1 mg/kg—max.: 20 mg), IV (0.05–0.1 mg/kg—max.: 5 mg) or rectally (0.5–1 mg/kg—max.: 20 mg), and some also received atropine IM (0.02 mg/kg) or IV (0.01 mg/kg). Authors applied an induction with sevoflurane at 8% and FiO2 at 100% and maintenance 1 to 2 minutes after with 2 to 4 vol%. Regarding the ketamine group, doses were reported between 5 and 7 mg/kg IM. One patient was excluded as he required intubation in the sevoflurane group, plus 3 patients whose IOP, after randomized, could not be measured. The IOP baseline measurement was taken immediately after induction (T1); therefore, values of awake patients were not collected. The T1 time ranged between 3 and 10 minutes after induction. Other values were recorded at minutes 2, 4, 6, and 8.

In order to approximate to the basal IOP, they made a regression of the best adjustment by extrapolating data backwards, and found the cross point of both variables between 2 and 4 minutes previous to the T1. Medians for IOP taken in T1 between the 2 groups reported no differences (P=0.15). With sevoflurane, a greater and more consistent decrease was reported at minutes 2, 4, 6, and 8 after induction when compared to T1, of 11.5%, 19.2%, 18.5%, and 16.7%, respectively (P<0.001). The ketamine group reported IOP decrease at times measured, but its variation with respect to T1 was not clinically significant (7.4%), even if the result was statistically relevant (P=0.03), with a 95% assumed confidence interval (CI) with 5% of error. These data were not reported in the article.

Jones et al28 intended to describe changes in IOP after intramuscular or intravenous ketamine administration and final maintenance with sevoflurane, through retrospective review of cases. They reviewed clinical histories for a period of 3 years and assessed patients unable to cooperate subject to examinations under anesthesia (EUA) and unreliable measurements taken to patients awake. 5 mg/kg IM or 2 mg/kg IV of ketamine were administered. Measurements were averaged in groups of 3 (alternately between the 2 eyes). They found an average difference between ketamine measurements and sevoflurane measurements of 7.39 mm Hg (P<0.001), 28.5% less with sevoflurane. The mean IOP value was 17.0 mm Hg in the sevoflurane group and 24.4 mm Hg in the ketamine group.

Drayna et al29 prospectively recruited patients to perform a descriptive analysis of the impact of different doses of ketamine on the IOP of pediatric patients
scheduled for procedures under sedation with this drug. They calculated the basal IOP by measuring it in both eyes and averaging it before administering ketamine. They found no clinically or statistically significant increase between baseline and IOP measurements performed at minutes 1, 3, 5, 15, and 30 (P=0.15). A Bland Altman’s analysis showed an appropriate level of concordance between the measurements of each eye at different times. The association of ketamine doses with IOP was not statistically significant (P=0.90); the average IV dose was 1.88 (mg/kg). The mean values were: baseline 14.66 mm Hg, 1 minute 14.84 mm Hg, 3 minutes 15.18 mm Hg, 5 minutes 15.46 mm Hg, and 15 minutes 15.75 mm Hg.

Halstead et al. proposed a non-inferiority study including pediatric ASA I or II patients scheduled for procedures under sedation with ketamine for problems other than eye injury, in which all patients received ketamine at doses between 1 and 2 mg/kg IV, and were controlled with baseline values taken immediately after the medication was administered. According to their findings, there were no clinically significant changes in IOP (>15%, 2.6 mm Hg); these results were applied to the 3 age groups in the study: 1 to 5, 6 to 10, and 11 to 15 years. In their results, the mean value of initial IOP was 17.5 and 18.9 mm Hg at 2.5 minutes, with an average difference between the 2 measurements of 1.4 mm Hg.

Wadia et al. in their prospective observational study using a convenience sample that included children up to 18 years of age, performed baseline measurements of IOP before administering procedural sedation with ketamine in Emergency. The average increase in IOP was 3 mm Hg (0–8 mm Hg). They reported the results descriptively, using 95% Clopper–Pearson CIs, averages and medians, as applicable.

Van der Walt et al. studied children with glaucoma or suspected glaucoma who required evaluation under anesthesia. Anesthesia was protocolized: induction with sevoflurane, peripheral vein channeling, IV administration of ketamine at 2 mg/kg and maintenance with ketamine infusion at 4 mg/kg/h for 15 minutes. Comparing the mean IOP at time 0 (sevoflurane only) with time 15 minutes (ketamine only), an increase of 3.68 mm Hg in IOP (95% CI 1.35–6.02 mm Hg) (P=0.002) was shown. Comparing the mean IOP at 15 minutes (ketamine alone) and 20 minutes (near awakening), there was an increase of 0.28 mm Hg (P=0.826).

The evaluation of the quality of the evidence made it possible to identify that the studies by Yoshikawa et al, Ausinsch et al, Nagdev et al, Blumberg et al, and Jones et al have deficiencies in reporting the methodology used to recruit patients, determine losses and participation percentage, justify sample sizes and describe the statistical power sought. Some also presented difficulties in their methodology for measuring the effect of different drug doses (ketamine) on intraocular pressure (primary outcome). Only the study by Nagdev et al speaks of double blinding, and in the other studies they do not report it or deny having done it in their manuscripts.

According to the evaluation carried out with the QAT-NIH instrument, it was concluded that the studies of Yoshikawa, Ausinsch, and Jones are of poor quality, those of Nagdev, Blumberg, Halstead, Drayna, and Wadia are of acceptable quality, and that of Van der Walt is of good quality.

In terms of complications and safety, the first to report results were Nagdev et al, who in their work found that higher doses (6 mg/kg IM) compared with doses of 3 mg/kg IM produced a greater number of airway complications (obstruction), with 18 patients vs. 4. Sedation at 0 and 2 hours after the procedure was higher in the high-dose group: for immediate postprocedure (0 hours) there were 13 patients compared with 8 in the low-dose group, and at 2 hours postprocedure there were 19 patients compared with 2 in the low-dose group. All these comparisons showed differences between the study groups (P < 0.005).

In the experience of Van der Walt et al, these authors refer in their methodology to having recorded the presentation of complications; however, there is no report in the results of their work on whether or not complications occurred during the study. No other studies included in the analysis of this manuscript accounted for or reported the occurrence of complications.

The bias risk of the Blumberg et al. work assessed with the Cochrane risk-of-bias tool for individual studies identified as high-risk sources the lack of blinding of participants and staff and assessment of results. In the case of Halstead et al. the sources described above, plus the absence of a random sequence for the selection of patients and the concealment of the selection, made it a work with a high risk of bias, according to the same tool. For its part, the study by Nagdev et al. was the work with the lowest risk of bias among those evaluated; the only source identified as an uncertain risk of bias was the blinding of participants and staff, as its description was not completely clear in the manuscript. The results of these evaluations are shown in Fig. 2A and 2B.

Discussion

As previously mentioned, IOP measurement is of paramount importance for glaucoma diagnosis, follow-up, and treatment; however, in young children, who are unable to collaborate to make the measurement possible or at least 1 reliable measurement, it is necessary to perform it under anesthesia. The problem is that it has been widely described how sedative and anesthetic medications decrease intraocular pressure, and therefore it is important to find an option that produces no effect on it, for the measurement to be reliable and not affect the evaluation and adequate clinical analysis of patients and their therapeutic needs.
This systematic review aimed to assess the impact of ketamine administration on intraocular pressure in the pediatric population. The results, although of low quality of evidence, suggest that the administration of ketamine in pediatric patients to perform oculomotor tonometry has little or no effect on intraocular pressure. Of the 9 articles included in the review, 2 showed a statistically or clinically significant impact on the measurement of intraocular pressure following ketamine administration, and 7 others had results supporting their use in conducting these examinations. In studies that showed a significant impact of ketamine on IOP, doses of ketamine were higher (>4 mg/kg). Doses of up to 0.96 mg/kg in bolus were also documented, which produced appropriate conditions for tonometry in terms of sedation.

The limitations of this review are due to the heterogeneity of the studies in terms of population size and doses used of ketamine, the high risk of bias of several of the components of the included studies, and the lack of good quality studies to determine recommendations with stronger evidence. The use of ketamine by different routes (IM and IV) causes doses and instauration times of clinical effect to vary for IOP measurement. The impossibility of performing a meta-analysis due to the difficulties described in the methodology is another limitation.

Ausinsch et al. found a slight decrease in IOP after intramuscular administration of ketamine in the initial dose and in a second dose. Their population was small and they performed several co-interventions, a situation that negatively affects the strength of their methodology. They administered a small subgroup neuromuscular relaxation and further divided the main group into single and repeated doses of ketamine. It is difficult to assess the actual weight of the administration of a single drug on the outcome to be measured, and for this reason the final assessment of the quality of evidence in this study was not satisfactory.

For other studies evaluated in the review, such as Halstead et al. and Jones et al., a major difficulty was the adequate identification of an IOP baseline to determine the actual impact of ketamine administration. In some cases, the patient was under the effects of inhaled anesthetics, and in others measuring intraocular pressure in uncooperative conscious children resulted in unreliable values sometimes even greater than the patient’s normal values.

In the best quality studies (acceptable and good in QAT-NIH) no significant changes in IOP were reported at doses from 0.96 to 2 mg/kg IV, and from 3 to 5 mg/kg IM. However, no available evidence was found on the administration of ketamine by other routes to perform eye tonometry in children, and for this reason it is not possible to identify an appropriate dose for alternative routes with the evaluation of the present review; a systematic review of the literature identified the use of ketamine and its effectiveness intranasally with good results in terms of sedation and analgesia.

The results of this work do not allow us to recommend the use of ketamine as a general anesthetic for the measurement of intraocular pressure in children; although most of the results of the studies evaluated show little or no impact on this, there are no studies which methodological strength allows the recommendation to be made. Clinical trials with larger populations and greater methodological strength are still required.

**Conclusion**

Ketamine is a reliable anesthetic drug that may have less effect on intraocular pressure than other drugs used for the same purpose; however, the studies found do not have the necessary characteristics to consider assertively recommending this drug for EUA in children with glaucoma. It is therefore necessary to expand the evidence by conducting clinical trials with greater statistical force that would allow its use to be recommended in a protocol manner.

In case it is used among the different existing alternatives, clinicians should know that the available evidence, although of low quality, is inclined to show it as a safe and reliable choice for measurement, based on the safety results of the only article that reports them and on the variations shown in absolute terms in intraocular pressure in the different included studies, where values ranging from 1.4 mm Hg to a maximum of 3 mm Hg were found that are not clinically relevant for the diagnosis and follow-up of the pathology.

**Ethical responsibilities**

1. The results and conclusions reported in the document are true to what is described in the literature, without alterations or modifications made by the authors to adjust their results.
2. The written production is the product of the intellectual exercise of the authors, appropriately referencing in each of the relevant cases the references that correspond to other authors outside the work team.

**Financing**

The authors declare they have not received any type of funding from third parties for the conduction, search and reporting of this review.

**Conflicts of interest**

The authors declare there are no academic, economic or political conflicts of interest that would interfere with the transparent reporting of the results of this review.
References

Annex 1

**ScienceDirect (Elsevier)**

“ketamine” AND “intraocular pressure” OR “ocular tonometry” AND “children”.

**PubMed**

(“Ketamine”[Mesh]) AND (“Intraocular Pressure”[Mesh]) AND (“Child”[Mesh]) OR (“Child, Preschool”[Mesh]) AND (“Tonometry, Ocular”[Mesh]) AND (“Pragmatic Clinical Trial” [Publication Type] OR “Controlled Clinical Trial” [Publication Type] OR “Clinical Trial, Phase IV” [Publication Type] OR “Clinical Trial, Phase II” [Publication Type] OR “Clinical Trial, Phase I” [Publication Type] OR “Randomized Controlled Trial” [Publication Type] OR “Clinical Trial” [Publication Type] OR “Adaptive Clinical Trial” [Publication Type]) OR “Equivalence Trial” [Publication Type] OR “Cross-Over Studies” [Mesh] OR “Clinical Trial, Phase III” [Publication Type]).

**Ovid (Wolters Kluwer)**

“Ketamine AND Intraocular Pressure AND Ocular tonometry AND Children AND Clinical Trial AND Randomized Controlled Trial NOT Adults.”

**LILACS**

(tw: [Ketamine]) AND (tw: [Intraocular pressure]) OR (tw: [Ocular Tonometry]) AND (tw: [Children]) OR (tw: [Child]) (LILACS).

**Cochrane Index Clinical trials**

“Ketamine” AND “Intraocular pressure” AND “Children.”